Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioLargo, Inc. is a U.S.-based environmental technology company focused on developing and commercializing solutions for water treatment, air quality control, odor management, and advanced energy storage. The company operates at the intersection of environmental engineering, clean technology, and public health, with revenue primarily driven by technology licensing, product sales, and service agreements tied to proprietary platforms. BioLargo’s offerings are designed to address regulatory-driven and mission-critical problems, including PFAS contamination, industrial odors, and antimicrobial protection in healthcare settings.
Founded in the early 1990s and later reoriented toward environmental technologies, BioLargo evolved through internal research and targeted acquisitions to build a portfolio of patented solutions. Its strategic positioning emphasizes low-energy, high-efficacy technologies that are intended to outperform conventional alternatives on cost, sustainability, or performance. The company primarily serves municipal utilities, industrial operators, healthcare facilities, and commercial partners seeking differentiated environmental solutions.
Business Operations
BioLargo operates through several core business units that commercialize distinct technologies. BioLargo Water focuses on water and wastewater treatment using the Aqueous Electrostatic Concentrator (AEC) platform, which is designed to remove low-concentration contaminants such as PFAS, pharmaceuticals, and nutrients. Clyra Medical Technologies, a majority-owned subsidiary, develops and markets antimicrobial wound care products based on copper-iodine chemistry, generating recurring revenue through medical product sales.
Additional operations include Odor-No-More, which provides odor and VOC control solutions for industrial, municipal, and commercial facilities, and BioLargo Energy Technologies, which is developing advanced battery technologies, including sodium-based energy storage systems. BioLargo conducts most of its research, engineering, and early commercialization activities domestically, while pursuing partnerships and pilot projects to enable broader deployment. Some technologies remain in pre-commercial or early commercialization stages, and revenue contributions vary by segment.
Strategic Position & Investments
BioLargo’s strategy centers on advancing proprietary technologies through pilot validation, regulatory acceptance, and partnerships with established operators or manufacturers. Growth initiatives emphasize scaling the AEC platform for regulated contaminants, expanding clinical and distribution channels for Clyra Medical Technologies, and progressing energy storage technologies toward commercial readiness. The company has historically favored capital-efficient development and licensing models rather than large-scale asset ownership.
Key investments include continued funding of BioLargo Water for PFAS treatment demonstrations and infrastructure-related opportunities, as well as internal investment in BioLargo Energy Technologies to address long-duration and stationary energy storage markets. BioLargo has also completed selective acquisitions, most notably Clyra Medical Technologies, to add near-term revenue and diversify its technology base. The company’s portfolio reflects exposure to emerging environmental and clean energy sectors, though commercialization timelines differ across platforms.
Geographic Footprint
BioLargo is headquartered in the United States, with principal operations, laboratories, and management based in California. The company’s primary markets are domestic, particularly within U.S. municipal water, industrial services, and healthcare sectors, where regulatory frameworks drive demand for its technologies.
Internationally, BioLargo has engaged in limited pilot projects, evaluations, and commercial discussions in Europe, Asia, and the Middle East, typically through partners or prospective customers. While global in technological ambition, its operational footprint and revenue base remain predominantly U.S.-centric based on publicly available information.
Leadership & Governance
BioLargo was founded and is led by executives with long tenures at the company, reflecting a strategy driven by internally developed intellectual property and continuity of vision. Leadership emphasizes scientific innovation, regulatory compliance, and long-term value creation through technology commercialization rather than rapid expansion.
Key members of the leadership team include:
- Dennis P. Calvert – President and Chief Executive Officer
- Stuart Aaron – Chief Financial Officer
- Todd C. Hoover – Chief Technology Officer
- Scott J. Smith – Senior Vice President of Business Development
The board and executive team collectively guide strategic priorities, capital allocation, and governance, with oversight informed by public company reporting obligations and long-term environmental impact objectives.